Fierce Biotech August 1, 2024
After more than 30 years, gene therapy trailblazer James Wilson M.D., Ph.D., is leaving the University of Pennsylvania. He will be spearheading two new companies meant to translate the scientific discoveries made in the school’s Gene Therapy Program, where he served as director, into new treatments.
“Forming these two new entities is the next step to accelerate the future of gene therapy and deliver therapeutics to patients significantly faster,” Wilson said in a July 31 release.
Wilson will be CEO of GEMMA Biotherapeutics and Franklin Biolabs, which will work in tandem to develop new gene therapies. GEMMABio will be the research and development side of things, while Franklin Biolabs, a genetic medicines contract research organization, will take on services and...
Today's Sponsors
Today's Sponsor